gtx-104
Generic: nimodipine·Code: GTx-104
gtx-104: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Grace Therapeutics, Inc. (GRCE) | Phase 3 |
FDA Decisions
FDA_MeetingAlignment with the FDA supporting the planned New Drug Application submission for GTx-104.(GRCE)
Frequently asked questions
Who is developing gtx-104?
gtx-104 is being developed by Grace Therapeutics, Inc..
What is gtx-104's latest FDA decision?
The most recent tracked FDA decision for gtx-104 is FDA_Meeting for Alignment with the FDA supporting the planned New Drug Application submission for GTx-104., dated April 9, 2025.
Get deeper analysis on gtx-104
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis